Evicenter
P&T meetings

Tovorafenib

RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

Also known as DAY101, TAK-580
Regulatory submission
Not announced
Launch
Not announced
155 sources

Section 6 of 6

References

155 sources

  1. Alshammari et al. (2026) (opens in a new tab)
  2. Amayiri et al. (2024) (opens in a new tab)
  3. Armstrong et al. (2009) (opens in a new tab)
  4. Armstrong et al. (2011) (opens in a new tab)
  5. ASHP AHFS DI Essentials tovorafenib monograph (2025) (opens in a new tab)
  6. Ater et al. (2012) (opens in a new tab)
  7. Avery and Hardy (2014) (opens in a new tab)
  8. Bandopadhayay et al. (2014) (opens in a new tab)
  9. Barbato et al. (2024) (opens in a new tab)
  10. Bates et al. (2022) (opens in a new tab)
  11. Bazer et al. (2026) (opens in a new tab)
  12. Bennebroek et al. (2025) (opens in a new tab)
  13. Blue Cross Blue Shield Association FEP medical policy 5.21.222 (2025) (opens in a new tab)
  14. Bouffet et al. (2023a) (opens in a new tab)
  15. Bouffet et al. (2023b) (opens in a new tab)
  16. Brizini et al. (2026) (opens in a new tab)
  17. Buhl et al. (2019) (opens in a new tab)
  18. CDA-AMC dabrafenib plus trametinib reimbursement review (2025) (opens in a new tab)
  19. Cherlow et al. (2019) (opens in a new tab)
  20. Chugai Pharmaceutical companion diagnostic announcement (2026) (opens in a new tab)
  21. ClinicalTrials.gov NCT01425008 (opens in a new tab)
  22. ClinicalTrials.gov NCT03429803 (opens in a new tab)
  23. ClinicalTrials.gov NCT03871257 (opens in a new tab)
  24. ClinicalTrials.gov NCT04166409 (opens in a new tab)
  25. ClinicalTrials.gov NCT05566795 (opens in a new tab)
  26. CMS advanced diagnostic laboratory tests list (2025) (opens in a new tab)
  27. Crotty et al. (2025) (opens in a new tab)
  28. DailyMed OJEMDA prescribing information (2025) (opens in a new tab)
  29. Damodharan et al. (2026) (opens in a new tab)
  30. Day One Biopharmaceuticals accelerated approval announcement (2024) (opens in a new tab)
  31. Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026) (opens in a new tab)
  32. Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026) (opens in a new tab)
  33. Day One Biopharmaceuticals Connecticut prescriber price disclosure (2025) (opens in a new tab)
  34. Day One Biopharmaceuticals EveryDay Support HCP support team page (opens in a new tab)
  35. Day One Biopharmaceuticals Form 10-K (2026) (opens in a new tab)
  36. Day One Biopharmaceuticals fourth quarter 2025 results (2026) (opens in a new tab)
  37. Day One Biopharmaceuticals OJEMDA support page (opens in a new tab)
  38. Day One Biopharmaceuticals preliminary 2025 revenue announcement (2026) (opens in a new tab)
  39. Day One Biopharmaceuticals Schedule 14D-9 (2026) (opens in a new tab)
  40. Day One Biopharmaceuticals Series A announcement (2020) (opens in a new tab)
  41. de Blank et al. (2016) (opens in a new tab)
  42. de Blank et al. (2017) (opens in a new tab)
  43. de Bont and Schouten-van Meeteren (2024) (opens in a new tab)
  44. Dodgshun et al. (2016) (opens in a new tab)
  45. EMA Ojemda medicine overview (2026) (opens in a new tab)
  46. EMA Ojemda product information (2026) (opens in a new tab)
  47. EMA Ojemda public assessment report (2026) (opens in a new tab)
  48. Embring et al. (2026) (opens in a new tab)
  49. Erker et al. (2024) (opens in a new tab)
  50. Falzon et al. (2018) (opens in a new tab)
  51. Fangusaro et al. (2019) (opens in a new tab)
  52. Fangusaro et al. (2021) (opens in a new tab)
  53. Fangusaro et al. (2024) (opens in a new tab)
  54. Fangusaro et al. (2025) (opens in a new tab)
  55. Farias de Alvarenga et al. (2026) (opens in a new tab)
  56. FDA accelerated approval announcement (2024) (opens in a new tab)
  57. FDA approval letter NDA 217700 (2024) (opens in a new tab)
  58. FDA multi-discipline review NDA 217700 and 218033 (2024) (opens in a new tab)
  59. FDA Ongoing Cancer Accelerated Approvals (2026) (opens in a new tab)
  60. FDA risk assessment and risk mitigation review NDA 217700 and 218033 (2024) (opens in a new tab)
  61. FDA supplement approval letter NDA 217700 (2025) (opens in a new tab)
  62. Figueira and Pigott (2026) (opens in a new tab)
  63. Fisher et al. (2012) (opens in a new tab)
  64. Forbrigger et al. (2026) (opens in a new tab)
  65. Foundation Medicine (2025) (opens in a new tab)
  66. G-BA benefit assessment procedure tovorafenib (2026) (opens in a new tab)
  67. G-BA Nutzenbewertung tovorafenib (2026) (opens in a new tab)
  68. Gajjar et al. (2025) (opens in a new tab)
  69. Gascon et al. (2024) (opens in a new tab)
  70. Gascon et al. (2026) (opens in a new tab)
  71. Giantini-Larsen et al. (2025) (opens in a new tab)
  72. Gnekow et al. (2012) (opens in a new tab)
  73. Gnekow et al. (2017) (opens in a new tab)
  74. Gnekow et al. (2019) (opens in a new tab)
  75. Grin et al. (2026) (opens in a new tab)
  76. Hammad et al. (2024) (opens in a new tab)
  77. Hanania et al. (2021) (opens in a new tab)
  78. Hargrave et al. (2026) (opens in a new tab)
  79. HAS OJEMDA early access decision (2026) (opens in a new tab)
  80. HTACG tovorafenib JCA report (2026) (opens in a new tab)
  81. HTACG tovorafenib JCA summary report (2026) (opens in a new tab)
  82. ICER Launch Price and Access Report (2025) (opens in a new tab)
  83. Ipsen and Day One Biopharmaceuticals licensing announcement (2024) (opens in a new tab)
  84. Ipsen EU approval announcement (2026) (opens in a new tab)
  85. Ipsen H1 2026 results (2026) (opens in a new tab)
  86. IPSEN Japan approval announcement (2026) (opens in a new tab)
  87. Ipsen Joint Clinical Assessment publication update (2026) (opens in a new tab)
  88. IQWiG dossier assessment G26-11 (2026) (opens in a new tab)
  89. IQWiG G26-11 project page (2026) (opens in a new tab)
  90. Jacob et al. (2011) (opens in a new tab)
  91. Jalal et al. (2025) (opens in a new tab)
  92. Jones et al. (2008) (opens in a new tab)
  93. Jones et al. (2013) (opens in a new tab)
  94. Kelada et al. (2020) (opens in a new tab)
  95. Khuong Quang et al. (2026) (opens in a new tab)
  96. Kilburn et al. (2024) (opens in a new tab)
  97. Kline et al. (2024a) (opens in a new tab)
  98. Kline et al. (2024b) (opens in a new tab)
  99. Kline et al. (2025) (opens in a new tab)
  100. Kline et al. (2026a) (opens in a new tab)
  101. Kline et al. (2026b) (opens in a new tab)
  102. Krishnatry et al. (2016) (opens in a new tab)
  103. Lafay-Cousin et al. (2008) (opens in a new tab)
  104. Lassaletta et al. (2016) (opens in a new tab)
  105. Lassaletta et al. (2017) (opens in a new tab)
  106. Lassaletta et al. (2024) (opens in a new tab)
  107. Louis et al. (2021) (opens in a new tab)
  108. Merchant et al. (2009) (opens in a new tab)
  109. Miser et al. (2023) (opens in a new tab)
  110. Musial-Bright et al. (2011) (opens in a new tab)
  111. NCCN Guidelines Pediatric Central Nervous System Cancers (opens in a new tab)
  112. NICE ID6557 project information (2025) (opens in a new tab)
  113. NICE TA977 (2024) (opens in a new tab)
  114. Nobre et al. (2020) (opens in a new tab)
  115. Nwachukwu et al. (2015) (opens in a new tab)
  116. Nysom et al. (2025) (opens in a new tab)
  117. O'Hare et al. (2024) (opens in a new tab)
  118. Peipert et al. (2024) (opens in a new tab)
  119. Perreault et al. (2019) (opens in a new tab)
  120. Pharma Japan (2026) (opens in a new tab)
  121. Picariello et al. (2026) (opens in a new tab)
  122. Price et al. (2025) (opens in a new tab)
  123. Raabe et al. (2011) (opens in a new tab)
  124. Rafia et al. (2026) (opens in a new tab)
  125. Ramagopalan and Pannelay (2026) (opens in a new tab)
  126. Rasco et al. (2023) (opens in a new tab)
  127. Rios et al. (2022) (opens in a new tab)
  128. Rocque et al. (2019) (opens in a new tab)
  129. Roka et al. (2024) (opens in a new tab)
  130. Roser et al. (2019) (opens in a new tab)
  131. Ruggiero et al. (2026) (opens in a new tab)
  132. Ryall et al. (2020a) (opens in a new tab)
  133. Ryall et al. (2020b) (opens in a new tab)
  134. Servier (2026) (opens in a new tab)
  135. Servier acquisition completion announcement (2026) (opens in a new tab)
  136. Singh et al. (2025) (opens in a new tab)
  137. SIOPE Brain Tumour Group standard clinical practice recommendations (2022) (opens in a new tab)
  138. Stiller et al. (2019) (opens in a new tab)
  139. Stokland et al. (2010) (opens in a new tab)
  140. Sturm et al. (2023) (opens in a new tab)
  141. Styczewska et al. (2026) (opens in a new tab)
  142. Sun et al. (2017) (opens in a new tab)
  143. Tkacik et al. (2023) (opens in a new tab)
  144. Tsang et al. (2017) (opens in a new tab)
  145. Tsimicalis et al. (2011) (opens in a new tab)
  146. van Tilburg et al. (2024) (opens in a new tab)
  147. Warner et al. (2015) (opens in a new tab)
  148. Wen et al. (2022) (opens in a new tab)
  149. Williams et al. (2018) (opens in a new tab)
  150. Wilne et al. (2007) (opens in a new tab)
  151. Witt et al. (2025) (opens in a new tab)
  152. Wright et al. (2026) (opens in a new tab)
  153. Xu et al. (2026) (opens in a new tab)
  154. Zelt et al. (2024) (opens in a new tab)
  155. Zheng et al. (2026) (opens in a new tab)